A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 3,701–3,800 of 3,965
Blumhagen, R. Z., Kurche, J. S., Cool, C. D., Walts, A. D., Heinz, D. E., Fingerlin, T. E., Yang, I. V., & Schwartz, D. A. (2023) · Figshare · doi:10.6084/m9.figshare.24586039
Lee, J. H., Park, H. J., Kim, S., Kim, Y.-J., & Kim, H. C. (2024) · Figshare · doi:10.6084/m9.figshare.26566304
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646811
Aronson, K. I., Ali, M., Reshetynak, E., Kaner, R. J., Martínez, F. J., Safford, M. M., & Pinheiro, L. C. (2021) · Figshare · doi:10.6084/m9.figshare.13579039
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646820
Todd, J. L., Vinisko, R., Liu, Y., Neely, M. L., Overton, R. A., Flaherty, K. R., Noth, I., Newby, L. K., Lasky, J. A., Olman, M. A., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11986254
Ghosh, A. J., Hobbs, B. D., Yun, J. H., Saferali, A., Moll, M. R., Xu, Z., Chase, R. P., Morrow, J. D., Ziniti, J. P., Sciurba, F., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19634917
Additional file 2 of Standardised 3D-CT lung volumes for patients with idiopathic pulmonary fibrosis
Tanaka, Y., Suzuki, Y., Hasegawa, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19959619
Marijic, P., Schwarzkopf, L., Schwettmann, L., Ruhnke, T., Trudzinski, F., & Kreuter, M. (2021) · Figshare · doi:10.6084/m9.figshare.16835197
Barth, S. E., Edwards, C. C., Saini, G., Haider, Y., Williams, N., Storrar, W., Jenkins, G. R., Stewart, I. D., & Wickremasinghe, M. I. Y. (2024) · Figshare · doi:10.6084/m9.figshare.25608744
Ikeda, K., Chiba, H., Nishikiori, H., Azuma, A., Kondoh, Y., Ogura, T., Taguchi, Y., Ebina, M., Sakaguchi, H., Miyazawa, S., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13311127
Wang, H.-Y., Tsai, S.-C., Lin, Y.-C., Hou, J.-U., & Chao, C.-H. (2024) · Figshare · doi:10.6084/m9.figshare.26701147
Marijic, P., Schwarzkopf, L., Schwettmann, L., Ruhnke, T., Trudzinski, F., & Kreuter, M. (2021) · Figshare · doi:10.6084/m9.figshare.16835200
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.24670286
Yamagata, A., Arita, M., Tachibana, H., Tokioka, F., Sugimoto, C., Sumikawa, H., Tanaka, T., Yasui, H., Fujisawa, T., Nakamura, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14457401
Cano-Jiménez, E., Romero Ortiz, A. D., Villar, A., Rodríguez-Nieto, M. J., Ramón, A., & Armengol, S. (2022) · Figshare · doi:10.6084/m9.figshare.21062151
Özaltin, B., Chapman, R., Arfeen, M. Q. U., Fitzpatick, N., Hemingway, H., Direk, K., & Jacob, J. (2024) · Figshare · doi:10.6084/m9.figshare.26736267
Özaltin, B., Chapman, R., Arfeen, M. Q. U., Fitzpatick, N., Hemingway, H., Direk, K., & Jacob, J. (2024) · Figshare · doi:10.6084/m9.figshare.26736270
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646849
Zhang, H., Yang, Y., Cao, Y., & Guan, J. (2024) · Figshare · doi:10.6084/m9.figshare.26036523
Kizawa, R., Araya, J., & Fujita, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24180899
Additional file 2 of Identification of targetable kinases in idiopathic pulmonary fibrosis
Higo, H., Ohashi, K., Tomida, S., Okawa, S., Yamamoto, H., Sugimoto, S., Senoo, S., Makimoto, G., Ninomiya, K., Nakasuka, T., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19135954
Yang, X., Sun, W., Jing, X., Zhang, Q., Huang, H., & Xu, Z. (2022) · Figshare · doi:10.6084/m9.figshare.19565832
Wang, H.-Y., Tsai, S.-C., Lin, Y.-C., Hou, J.-U., & Chao, C.-H. (2024) · Figshare · doi:10.6084/m9.figshare.26701141
Rautajoki, T., Rantala, H. A., Sutinen, E., Saarto, T. H., Rajala, K., Pesonen, I., Hollmén, M., Myllärniemi, M., & Lehto, J. T. (2024) · Figshare · doi:10.6084/m9.figshare.27140887
Podolanczuk, A. J., Kim, J. S., Cooper, C. B., Lasky, J. A., Murray, S., Oldham, J. M., Raghu, G., Flaherty, K. R., Spino, C., Noth, I., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22611217
Additional file 1 of Lung function trajectories in patients with idiopathic pulmonary fibrosis
Neely, M. L., Hellkamp, A. S., Bender, S., Todd, J. L., Liesching, T. N., Luckhardt, T., Oldham, J. M., Raj, R., White, E. S., & Palmer, S. M. (2023) · Figshare · doi:10.6084/m9.figshare.24022888
Lai, X., Lin, Y., Huang, S., Pu, L., Zeng, Q., Wang, Z., & Huang, W. (2023) · Figshare · doi:10.6084/m9.figshare.24054621
Shi, H., Yin, D., Bonella, F., Kreuter, M., Oltmanns, U., Li, X., Peng, S., & 魏路清 (2020) · Figshare · doi:10.6084/m9.figshare.12269687
Lee, J. H., Park, H. J., Kim, S., Kim, Y.-J., & Kim, H. C. (2024) · Figshare · doi:10.6084/m9.figshare.26566310
Maqhuzu, P. N., Szentes, B. L., Kreuter, M., Bahmer, T., Kahn, N. C., Claussen, M., Holle, R., & Schwarzkopf, L. (2020) · Figshare · doi:10.6084/m9.figshare.13070884
Marijic, P., Schwarzkopf, L., Schwettmann, L., Ruhnke, T., Trudzinski, F., & Kreuter, M. (2021) · Figshare · doi:10.6084/m9.figshare.16835206
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646840
Additional file 1 of Standardised 3D-CT lung volumes for patients with idiopathic pulmonary fibrosis
Tanaka, Y., Suzuki, Y., Hasegawa, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19959616
Additional file 1 of Cost drivers in the pharmacological treatment of interstitial lung disease
Maqhuzu, P. N., Kreuter, M., Bahmer, T., Kahn, N. C., Claussen, M., Holle, R., & Schwarzkopf, L. (2021) · Figshare · doi:10.6084/m9.figshare.15103002
Wang, H.-Y., Tsai, S.-C., Lin, Y.-C., Hou, J.-U., & Chao, C.-H. (2024) · Figshare · doi:10.6084/m9.figshare.26701120
Keow, J., Cecchini, M. J., Jayawardena, N., Zompatori, M., JOSEPH, M. G., & Mura, M. (2022) · Figshare · doi:10.6084/m9.figshare.20024700
Yang, F., Du, W., Tang, Z., Wei, Y., & Dong, J. (2023) · Figshare · doi:10.6084/m9.figshare.22617848
Biondini, D., Cocconcelli, E., Bernardinello, N., Lorenzoni, G., Rigobello, C., Lococo, S., Castelli, G., Baraldo, S., Cosío, M. G., Gregori, D., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14361399
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646834
Chen, T., Tsai, A. P. Y., Hur, S. A., Wong, A. W., Sadatsafavi, M., Fisher, J. H., Johannson, K. A., Assayag, D., Morisset, J., Shapera, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14936197
He, Z., Wang, R., Song, C., Liu, J., Chen, R., Zheng, M., Liu, W. L., Jiang, G., & Mao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26695971
Maqhuzu, P. N., Szentes, B. L., Kreuter, M., Bahmer, T., Kahn, N. C., Claussen, M., Holle, R., & Schwarzkopf, L. (2020) · Figshare · doi:10.6084/m9.figshare.13070881
Corral, M., DeYoung, K., & Kong, A. M. (2020) · Figshare · doi:10.6084/m9.figshare.12644635
Ikeda, K., Chiba, H., Nishikiori, H., Azuma, A., Kondoh, Y., Ogura, T., Taguchi, Y., Ebina, M., Sakaguchi, H., Miyazawa, S., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13311124
Wu, M., Wang, Z., Shi, X., Zan, D., Chen, H., Yang, S., Ding, F., Yang, L., Tan, P., Ma, R. Z., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24144030
Todd, J. L., Vinisko, R., Liu, Y., Neely, M. L., Overton, R. A., Flaherty, K. R., Noth, I., Newby, L. K., Lasky, J. A., Olman, M. A., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11986272
Lee, J. H., Park, H. J., Kim, S., Kim, Y.-J., & Kim, H. C. (2024) · Figshare · doi:10.6084/m9.figshare.26566307
Todd, J. L., Vinisko, R., Liu, Y., Neely, M. L., Overton, R. A., Flaherty, K. R., Noth, I., Newby, L. K., Lasky, J. A., Olman, M. A., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11986263
Wang, H.-Y., Tsai, S.-C., Lin, Y.-C., Hou, J.-U., & Chao, C.-H. (2024) · Figshare · doi:10.6084/m9.figshare.26701150
Yamagata, A., Arita, M., Tachibana, H., Tokioka, F., Sugimoto, C., Sumikawa, H., Tanaka, T., Yasui, H., Fujisawa, T., Nakamura, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14457407
Wang, B., Wang, Y., Chen, H. J., Yao, S., Lai, X., Qiu, Y., Cai, J., Huang, Y., Wei, X., Guan, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.13605590
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646843
Barth, S. E., Edwards, C. C., Saini, G., Haider, Y., Williams, N., Storrar, W., Jenkins, G. R., Stewart, I. D., & Wickremasinghe, M. I. Y. (2024) · Figshare · doi:10.6084/m9.figshare.25608868
Chu, K.-A., Yeh, C.-C., Kuo, F.-H., Lin, W.-R., Hsu, C.-W., Chen, T.-H., & Fu, Y.-S. (2020) · Figshare · doi:10.6084/m9.figshare.13311121
Biondini, D., Cocconcelli, E., Bernardinello, N., Lorenzoni, G., Rigobello, C., Lococo, S., Castelli, G., Baraldo, S., Cosío, M. G., Gregori, D., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14361408
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646837
Lin, T., Zhou, F., Mao, H., Xie, Z., & Jin, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26612405
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646823
Additional file 1 of Plasma metabolomics and quantitative interstitial abnormalities in ever-smokers
Choi, B., Estépar, R. S. J., Godbole, S. V., Curtis, J. L., Wang, J. M., Estépar, R. S. J., Rosas, I. O., Mayers, J. R., Hobbs, B. D., Hersh, C. P., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26635839
Todd, J. L., Vinisko, R., Liu, Y., Neely, M. L., Overton, R. A., Flaherty, K. R., Noth, I., Newby, L. K., Lasky, J. A., Olman, M. A., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11986296
Chen, C.-Y., Chen, C.-H., Wang, C.-Y., Lai, C.-C., Chao, C.-M., & Wei, Y.-F. (2021) · Figshare · doi:10.6084/m9.figshare.16625486
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646832
Xu, F., Tong, Y., Yang, W., Cai, Y., Yu, M., Liu, L., & Meng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.25422324
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646846
Wang, H.-Y., Tsai, S.-C., Lin, Y.-C., Hou, J.-U., & Chao, C.-H. (2024) · Figshare · doi:10.6084/m9.figshare.26701126
Wu, X., Gou, H., Ou, Z., Qiu, H., Liu, H., Fu, Z., & Chen, L. (2022) · Figshare · doi:10.6084/m9.figshare.21258279
Keow, J., Cecchini, M. J., Jayawardena, N., Zompatori, M., JOSEPH, M. G., & Mura, M. (2022) · Figshare · doi:10.6084/m9.figshare.20024703
Biondini, D., Cocconcelli, E., Bernardinello, N., Lorenzoni, G., Rigobello, C., Lococo, S., Castelli, G., Baraldo, S., Cosío, M. G., Gregori, D., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14361405
Yamagata, A., Arita, M., Tachibana, H., Tokioka, F., Sugimoto, C., Sumikawa, H., Tanaka, T., Yasui, H., Fujisawa, T., Nakamura, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14457398
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646814
Patel, A. S., Miller, E. R., Regis, S. M., Hunninghake, G. M., Price, L. L., Gawlik, M., McKee, A. B., Rieger-Christ, K. M., Pinto-Plata, V., Liesching, T. N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26568463
Rautajoki, T., Rantala, H. A., Sutinen, E., Saarto, T. H., Rajala, K., Pesonen, I., Hollmén, M., Myllärniemi, M., & Lehto, J. T. (2024) · Figshare · doi:10.6084/m9.figshare.27140902
Wang, H.-Y., Tsai, S.-C., Lin, Y.-C., Hou, J.-U., & Chao, C.-H. (2024) · Figshare · doi:10.6084/m9.figshare.26701153
Short Telomere Syndrome and Interstitial Lung Diseases: An Updated Clinical Review (2025)
Ahmed, S. (2025) · PULMON · doi:10.4103/pulmon.pulmon_26_25 · Cited by 1
Ratsimandresy, R. A., Doran, E., Dengler, H. S., Headland, S. E., Wedeles, C. J., Guidi, R., Xu, D., Liu, J., Shi, Y., Wang, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.25.695625 · Cited by 1
Regulatory T cells protect against aberrant remodeling in a mouse model of pulmonary fibrosis
Murthy, A., Rodriguez, L. R., Barboza, W. R., Tomer, Y., Bui, S., Carson, P., Dimopoulos, T. T., Iyer, S., Chavez, K., Cooper, C. H., et al. (2025) · Mucosal Immunology · doi:10.1016/j.mucimm.2025.12.004 · Cited by 3
“6 The dearth of IPF therapeutics can be linked in part to an incomplete understanding of its pathophysiologic underpinnings.”
Wang, B., Liang, M., Wang, Q., Chang, J., Liu, W., & Gao, C. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100302 · Cited by 2
Schwalbach, K. T., & Hemnes, A. R. (2025) · Respiratory medicine · doi:10.1007/978-3-032-03581-3_6
Carolan, A. (2026) · Current Geriatrics Reports · doi:10.1007/s13670-025-00452-z
STL1267 inhibits myofibroblast differentiation in a TGFβ1-driven human lung fibroblast model
Prasad, C., Huang, S. K., Burris, T. P., & Sundar, I. K. (2026) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00561.2025
Zhang, Z., Fang, X., Gao, J., Sun, H., Xu, T., & Wang, J. (2026) · Canadian Respiratory Journal · doi:10.1155/carj/8812779 · Cited by 2
“Multiple studies have demonstrated that pirfe-nidone may attenuate the decline in lung function by approximately 50% and lower the relative risk (RR) of death by about 48% in IPF patients [10, 11].”
Zhou, X., Sima, M., Fang, Z., Cui, Y., Han, M., Wang, Y., Liu, J., Bi, Y., & Yue, D. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1734512 · Cited by 2
Arai, T., Otsuka, J., Akagawa, S., et al. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2025.101361
Zhou, Z., Han, S., Duan, Y., Hong, M., & Huang, J. (2026) · Analytical Cellular Pathology · doi:10.1155/ancp/1319659
Yamazaki, A., Yamazaki, R., Kita, M., Kubo, T., Noma, S., Hashimoto, S., Taguchi, Y., & Ishida, T. (2026) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-025-01790-2
崔, 文. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.161343
Current and Emerging Biomarkers in Interstitial Lung Disease
Hulme, K. M., Chen, K., Reddy, T. L., & Troy, L. (2026) · Respiratory The American Medical Journal · doi:10.33590/respiramj/hirk8895 · Cited by 1
From Pixels to Prognosis: An AI Framework for Volumetric RALE Scoring in Post-COVID Chest CT
Garea-Llano, E., Larrinaga, Á. R. E., Arencibia, M., & Dalmau, E. G. (2026) · Lecture notes in computer science · doi:10.1007/978-3-032-11358-0_1
Fu, C., Jing, X. B., Zhang, M., Cheng, Y., Yang, W., Wu, X., Chu, X., & Lu, X. (2026) · Biochemical Genetics · doi:10.1007/s10528-026-11325-1
Dust from the Past: Asbestos Related Lung Disease, a Disease of the Elderly
Tan, A. Y. Y., & Thong, L. (2026) · Current Geriatrics Reports · doi:10.1007/s13670-025-00455-w · Cited by 1
Prioritizing Therapeutic Targets for Interstitial Lung Disease: A Causal Mediation AnalysisPreprint
Oldham, J., Molyneaux, P. L., Maddali, M. V., Newton, C. A., Kim, J. S., Konkol, S., Pugashetti, J. V., Liu, G. Y., Goobie, G. C., Adegunsoye, A., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8714555/v1
Zhu, H., Chen, M., Li, Q., Cui, S., Jiang, C., Ye, X., Hou, S., Zhang, J., Huang, X., & Cao, M. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02053-2
Qin, C., yu, K., Li, Y., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8506344/v1
Chen, W., Peng, J., Tang, X., Xiao, Y., Chen, Y., Tang, L., & Ouyang, S. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112445
Philippot, Q., Guyard, A., Debray, M., & Crestani, B. (2026) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(26)51478-5
Kim, J., Sun, J., Shin, Y. A., Kim, M., Kim, T. K. T., MinJeong, J., La, M. T., Yang, S., Lee, B., Lee, Y.-S., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118733
Economic Burden of Idiopathic Pulmonary Fibrosis: Updated Evidence on Costs and Resource Use
Diamantopoulos, A., Pople, O., Godman, A., & Papastergios, E. (2026) · PharmacoEconomics · doi:10.1007/s40273-026-01600-9
Nintedanib and Pirfenidone Affect Growth and Differentiation of Human Alveolar Type 2 CellsPreprint
Bazarov, A. V., Serra-Marques, A., Protti, G., Yang, M. M., Naikawadi, R. P., Green, G. A., Lee, S., Kukreja, J., Matthay, M. A., Wax, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.02.708135
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.